🇺🇸 SRPT — Sarepta Therapeutics, Inc.

Salud Mantener
← Volver

Precio actual

17,82 USD

Máx. histórico

178,74

2145 días

Split 1:6 del 12/07/2012

Caída desde máximo

-90,03%

Rango 52 semanas

14,68 – 24,68

Variación hoy

+1,42%

Cierre anterior

17,57

Rango de hoy

17,52 – 18,77

Volumen hoy

2.596.193

Peor caída histórica

-98,17%

09/02/2000 → 18/12/2008

Recuperado en 3568 días

Volatilidad anualizada ⓘ

95,43%

Información
Nombre completo
Sarepta Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
835
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
21,64 USD (puede no estar actualizado)
Primera cotización
04/06/1997
Precio actualizado
hace 12 horas
Sobre la empresa

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Splits Registrados en el histórico de precios
Fecha Ratio
12/07/2012 1:6
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
08/01/2018 54,75 56,00 52,35 54,02 -1,55% 6,67% 3.619.900
05/01/2018 58,22 58,22 54,20 54,87 -5,09% 6,90% 3.110.700
04/01/2018 59,62 59,95 57,58 57,81 -1,26% 3,98% 1.874.300
03/01/2018 58,59 59,00 57,62 58,55 +0,52% 2,36% 1.657.300
02/01/2018 55,87 58,47 55,12 58,25 +4,69% 6,00% 2.885.500
29/12/2017 56,60 56,97 55,62 55,64 -1,71% 2,39% 986.400
28/12/2017 56,70 57,09 56,25 56,61 -0,25% 1,48% 753.900
27/12/2017 56,79 57,31 56,20 56,75 +0,42% 1,95% 941.500
26/12/2017 55,95 56,88 55,95 56,51 +0,96% 1,66% 989.100
22/12/2017 55,22 56,82 55,15 55,97 +1,27% 3,02% 1.318.900
21/12/2017 54,99 56,10 54,48 55,27 +0,40% 2,95% 1.179.800
20/12/2017 54,38 55,52 53,95 55,05 +1,55% 2,89% 1.287.400
19/12/2017 54,01 55,29 53,64 54,21 +0,22% 3,05% 1.274.100
18/12/2017 52,82 54,30 52,67 54,09 +2,83% 3,09% 1.540.700
15/12/2017 53,71 54,06 52,10 52,60 -1,96% 3,65% 2.403.600
14/12/2017 54,06 54,44 53,20 53,65 -0,81% 2,29% 1.153.400
13/12/2017 52,92 54,40 51,65 54,09 +1,98% 5,20% 1.781.600
12/12/2017 54,97 55,05 52,41 53,04 -2,25% 4,80% 1.758.900
11/12/2017 54,36 54,86 53,11 54,26 +0,00% 3,22% 2.467.200
08/12/2017 54,44 55,45 53,91 54,26 +1,01% 2,83% 1.384.100
07/12/2017 52,71 54,36 52,53 53,72 +2,21% 3,47% 1.581.700
06/12/2017 52,29 52,96 51,32 52,56 +0,40% 3,14% 1.155.000
05/12/2017 54,20 55,08 52,03 52,35 -3,57% 5,63% 1.256.400
04/12/2017 56,05 56,61 54,03 54,29 -1,74% 4,60% 1.227.600
01/12/2017 56,29 56,89 53,28 55,25 -0,75% 6,41% 1.714.900
30/11/2017 53,99 56,71 53,70 55,67 +3,59% 5,58% 1.857.700
29/11/2017 55,41 56,28 53,50 53,74 -3,61% 5,02% 1.579.000
28/11/2017 55,71 55,99 54,20 55,75 +0,52% 3,21% 984.500
27/11/2017 56,69 57,14 55,45 55,46 -2,03% 2,98% 1.298.200
24/11/2017 56,22 56,70 56,04 56,61 +0,69% 1,17% 365.500